Space Complexity Analysis of RSA and ECC Based Security Algorithms in Cloud Data

Cloud computing is an important development trend in information technology all over the world. Nowadays, the cloud data security technique exploits the symmetric encryption and asymmetric encryption algorithms within the capability of the stronger authentication techniques. A major risk of data security in cloud computing environment becomes a serious problem by reason of the data which is stored diversely over the cloud. Both the data security and privacy are the two main characteristics of cloud information technologies for user’s concern. We discuss in this paper, a number of existing techniques used to provide security in the field of cloud computing on the basis of different parameters. It will be helpful to improve assure the security of data storage in a cloud environment

Comparative of Delay Tolerant Network Routings and Scheduling using Max-Weight, Back Pressure and ACO

Network management and Routing is supportively done by performing with the nodes, due to infrastructure-less nature of the network in Ad hoc networks or MANET. The nodes are maintained itself from the functioning of the network, for that reason the MANET security challenges several defects. Routing process and Scheduling is a significant idea to enhance the security in MANET. Other than, scheduling has been recognized to be a key issue for implementing throughput/capacity optimization in Ad hoc networks. Designed underneath conventional (LT) light tailed assumptions, traffic fundamentally faces Heavy-tailed (HT) assumption of the validity of scheduling algorithms. Scheduling policies are utilized for communication networks such as Max-Weight, backpressure and ACO, which are provably throughput optimality and the Pareto frontier of the feasible throughput region under maximal throughput vector. In wireless ad-hoc network, the issue of routing and optimal scheduling performs with time varying channel reliability and multiple traffic streams. Depending upon the security issues within MANETs in this paper presents a comparative analysis of existing scheduling policies based on their performance to progress the delay performance in most scenarios. The security issues of MANETs considered from this paper presents a relative analysis of existing scheduling policies depend on their performance to progress the delay performance in most developments

Antimycobacterial activity of cyanobacterial species isolated from the coastal regions of Tamil Nadu

1165-1174The extract of Geitlerinema carotinosum CNP 4003 showed promising antimicrobial activity (100 and 1000 µg/disc/well) against E. coli ATCC 35218, S. aureus ATCC 25923, and M. smegmatis with inhibition zones of 6, 8, and 11 mm, respectively. In addition, the extract also exhibited cytotoxic activity (IC50 = 175 μg/ml) against mammalian (HepG2) liver cancer cell lines. Therefore, the crude extract was fractionated using column chromatography technique and the active fractions were identified. The active fractions tested against HepG2 cell line showed 95 % hemolytic activity at the concentration of 375 µg/ml with IC50 as 63 μg/ml. Further, the compounds in the active fractions were analyzed and the results indicated the presence of indoles, terpenes, and peptides. The chemical composition of the active fraction was analyzed by using gas chromatography-mass spectrometry (GC-MS). The potential antimycobacterial strain G. carotinosum CNP 4003 was confirmed by molecular characterization and the DNA sequence was deposited in the gene bank

Effects of surface material on growth pattern and bioactive exopolymers production of intertidal cyanobacteria Phormidium sp.

1669-1677A novel approach applying a conico-cylindrical flask (CCF) was used to study the growth of two morphologically identical Phormidium strains namely AP3 and AP9F. Further, the monosaccharide composition of the exopolysaccharide (EPS), its production, applicability in industrial processes and biological activity were evaluated. These evaluations were performed by employing contrasting cultivation modes (biofilm or planktonic) and different surface materials (hydrophobic polymethyl methacrylate (PMMA) and hydrophilic glass (G). Biofilm formation was seen to be elevated in PMMA-CCF cultivated Phormidium AP3 and AP9F than G-CCF mode. Among the two surface materials tested Phormidium AP3 and AP9F produced the highest amount of planktonic biomass in PMMA-CCF than in G-CCF mode. Average values of biofilm capsular/bound polysaccharide and polysaccharide released by cell suspension of Phormidium AP3 and AP9F were elevated in PMMA-CCF compared to the G-CCF setup. Protein concentrations in released polysaccharide (RPS) and biofilm of PMMA-CCF were higher in the Phormidium AP3 and AP9F when compared to the G-CCF cultivation. The antimicrobial, emulsifying and flocculating activities of EPS were assessed using standard assays

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.

AIMS: The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year. METHODS AND RESULTS: GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy. The mean (standard deviation) age was 69.8 (11.4) years, 43.8% were women, and the mean CHA2DS2-VASc score was 3.3 (1.6); 60.8% of patients were prescribed anticoagulant therapy with/without antiplatelet (AP) therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy. At 2-year follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-years, respectively. Rates for all three major events were highest during the first 4 months. Congestive heart failure, acute coronary syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and infection/sepsis accounted for 65% of all known causes of death and strokes for <10%. Anticoagulant treatment was associated with a 35% lower risk of death. CONCLUSION: The most frequent of the three major outcome measures was death, whose most common causes are not known to be significantly influenced by anticoagulation. This suggests that a more comprehensive approach to the management of NVAF may be needed to improve outcome. This could include, in addition to anticoagulation, interventions targeting modifiable, cause-specific risk factors for death. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

CLUSTER FORMATION OF ZOOPLANKTON AND ITS RELATION TO SEASONAL VARIATION

The survey of zooplankton was carried out in Plak Bay near to Mandapam. Regular fortnightly sample collections were made for two years from November 1993 to October 1995. A total of 81 species of zooplankton were observed during the study period. The abundance and distribution pattern of each and every species show direct relation to seasonal effect. The results also affirm significant cluster formation during the study period